ÂÜÀòÂÒÂ×

The founder and CEO of Fervent Pharmaceuticals, George Royster is responsible for overseeing and guiding the strategic direction of the company. He is currently preparing the company to conduct a Phase 2 trial, identifying strategic partners (subcontract partners, regulatory consultants, etc.) for outsourcing various aspects of the trial, and ensuring that the trial is adequately financed and successfully concluded.

As CEO, Mr. Royster has recruited the best collaborative strategic partners, including Quintiles and University of Iowa Pharmaceuticals. He has championed a successful Pilot Study of FP-101, demonstrating a 90% efficacy rate, and led the company to a successful Pre-IND meeting with the FDA.

Prior to starting Fervent Pharmaceuticals, Mr. Royster has over 25 years experience in healthcare executive management. He has assisted healthcare organizations in the areas of productivity and profitability by way of operations management, business and service line development. He is credited with over a dozen US and international patents, and is currently hard at work ensuring that Fervent is awarded its remaining international patents pending.

Mr. Royster was the Founder and CEO of a company that provided executive management, expertise, and oversight to healthcare systems, multi-specialty medical practices, and physican offices.

He holds a Bachelor of Business Administration degree from NC Wesleyan College.